Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 2
2014 3
2015 8
2016 4
2017 2
2018 3
2019 4
2020 7
2021 1
2022 4
2023 7
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, Klein SA, Schubert J, Niederland J, Kaufmann M, Schäfer-Eckart K, Schaich M, Baldauf H, Stölzel F, Petzold C, Röllig C, Alakel N, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Bornhäuser M, Mikesch JH, Schetelig J; Study Alliance Leukemia and the German Cooperative Transplant Study Group. Stelljes M, et al. Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4. Lancet Haematol. 2024. PMID: 38583455 Free article. Clinical Trial.
Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype.
Schumacher M, Beer S, Moraes Ribeiro E, Korkmaz F, Keppeler H, Fitzel R, Erkner E, Radszuweit P, Lengerke C, Schneidawind C, Hoefert S, Mauz PS, Schneidawind D. Schumacher M, et al. Among authors: schneidawind d. Front Oncol. 2024 Mar 7;14:1333640. doi: 10.3389/fonc.2024.1333640. eCollection 2024. Front Oncol. 2024. PMID: 38515578 Free PMC article.
Frequency and impact on renal transplant outcomes of urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
Brune JE, Dickenmann M, Sidler D, Walti LN, Golshayan D, Manuel O, Haidar F, Neofytos D, Schnyder A, Boggian K, Mueller TF, Schachtner T, Khanna N, Schaub S, Wehmeier C; Swiss Transplant Cohort Study. Brune JE, et al. Front Med (Lausanne). 2024 Feb 15;11:1329778. doi: 10.3389/fmed.2024.1329778. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38426162 Free PMC article.
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Moraes Ribeiro E, Secker KA, Nitulescu AM, Schairer R, Keppeler H, Wesle A, Schmid H, Schmitt A, Neuber B, Chmiest D, Podavini S, Märklin M, Klimovich B, Schmitt M, Korkmaz F, Lengerke C, Schneidawind C, Schneidawind D. Moraes Ribeiro E, et al. Among authors: schneidawind d. J Immunother Cancer. 2024 Jan 31;12(1):e007829. doi: 10.1136/jitc-2023-007829. J Immunother Cancer. 2024. PMID: 38296597 Free PMC article.
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal MA, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter JP; Swiss Blood Stem Cell Transplantation Group (SBST). Passweg JR, et al. Among authors: schneidawind d. Hematol Oncol. 2024 Jan;42(1):e3241. doi: 10.1002/hon.3241. Epub 2023 Dec 6. Hematol Oncol. 2024. PMID: 38058031
The RORɣ/SREBP2 pathway is a master regulator of cholesterol metabolism and serves as potential therapeutic target in t(4;11) leukemia.
Erkner E, Hentrich T, Schairer R, Fitzel R, Secker-Grob KA, Jeong J, Keppeler H, Korkmaz F, Schulze-Hentrich JM, Lengerke C, Schneidawind D, Schneidawind C. Erkner E, et al. Among authors: schneidawind d. Oncogene. 2024 Jan;43(4):281-293. doi: 10.1038/s41388-023-02903-3. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38030791 Free PMC article.
Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.
Rieger MJ, Stolz SM, Müller AM, Schwotzer R, Nair G, Schneidawind D, Manz MG, Schanz U. Rieger MJ, et al. Among authors: schneidawind d. Bone Marrow Transplant. 2023 Oct;58(10):1121-1129. doi: 10.1038/s41409-023-02042-z. Epub 2023 Jul 21. Bone Marrow Transplant. 2023. PMID: 37479752 Free PMC article.
49 results